Thought Leadership

 

Ensure your discussion guide’s English is not plain, but clear

One of the easiest traps in international primary research is assuming that “plain...

Using analogs to support your strategy

Whenever analogs come up in pharma strategy, someone usually says: “But that situation...

Wearables in Clinical Trials – Form Factor

Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on...

Why Your Advisory Board Shouldn’t Be Moderated by the Team

You’ve spent months working on the asset. The clinical strategy has been debated. The data...

Project History X: The Project That Outlived Its Parents

Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years...

Emerging Mechanisms in Obesity: NLRP3 inhibiton doesn’t move the scale

This past month, I have been immersed in obesity science, and one thing’s clear: not every...

Most Recent

Ensure your discussion guide’s English is not plain, but clear

One of the easiest traps in international primary research is assuming that “plain English” is automatically clear English. When preparing a primary...

Using analogs to support your strategy

Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the same as ours.” In recent weeks, I’ve...

Wearables in Clinical Trials – Form Factor

Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital cognitive assessments. Along the way, I came...

Why Your Advisory Board Shouldn’t Be Moderated by the Team Most Invested in the Answer

You’ve spent months working on the asset. The clinical strategy has been debated. The data have been reviewed from every angle. The...

All Posts

Ensure your discussion guide’s English is not plain, but clear

One of the easiest traps in international primary research is assuming that “plain English” is...

Using analogs to support your strategy

Whenever analogs come up in pharma strategy, someone usually says: “But that situation wasn’t the...

Wearables in Clinical Trials – Form Factor

Over recent months, I’ve been exploring novel diagnostic tools, with a particular focus on digital...

Why Your Advisory Board Shouldn’t Be Moderated by the Team Most Invested in the Answer

You’ve spent months working on the asset. The clinical strategy has been debated. The data have been...

Project History X: The Project That Outlived Its Parents

Every Project Plan Assumes People Don’t Leave. Reality Check: They Do. A few years ago, I took...

Emerging Mechanisms in Obesity: NLRP3 inhibiton doesn’t move the scale

This past month, I have been immersed in obesity science, and one thing’s clear: not every pathway...

Project History VII-IX: Why the Best Go/No-Go Research Starts by Trying to Kill the Project

Intro Teams often fail not because of a lack of data, but because of research that confirms what...

Its all to play for in the next generation of obesity treatments – Viking Therapeutics

It has been a quiet summer on the post front with holidays and then a few active projects keeping us...

What is Happening in Pain: The Next Wave of Sodium Channel Blockers

Intro At the end of May, Eli Lilly announced a $1 billion deal with Site One Therapeutics, a company...